Clinical trial
A Phase 3 Safety and Efficacy Study of Vitreosolve® for Ophthalmic Intravitreal Injection in Retinopathy Subjects
NCT00664183 is registered in ClinicalTrials.gov with Vitreoretinal Technologies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Safety and Efficacy Study of Vitreosolve® for Ophthalmic Intravitreal Injection in Retinopathy Subjects
- Lead sponsor
- Vitreoretinal Technologies, Inc.
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- March 31, 2008
- Completion date
- Not reported
- Enrollment
- 400 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.